149 related articles for article (PubMed ID: 3124618)
1. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
2. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
3. Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.
Donnez J; Nisolle-Pochet M; Clerckx-Braun F; Sandow J; Casanas-Roux F
Fertil Steril; 1989 Jul; 52(1):27-30. PubMed ID: 2501110
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
Lemay A; Maheux R; Jean C; Faure N
Prog Clin Biol Res; 1986; 225():157-73. PubMed ID: 3097663
[No Abstract] [Full Text] [Related]
5. Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase.
Lemay A; Sandow J; Bureau M; Maheux R; Fontaine JY; Mérat P
Fertil Steril; 1988 Mar; 49(3):410-7. PubMed ID: 3125068
[TBL] [Abstract][Full Text] [Related]
6. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Lemay A; Quesnel G
Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
[TBL] [Abstract][Full Text] [Related]
7. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
8. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
9. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis.
Fraser HM; Sandow J; Cowen GM; Lumsden MA; Haining R; Smith SK
Fertil Steril; 1990 Jan; 53(1):61-8. PubMed ID: 2104808
[TBL] [Abstract][Full Text] [Related]
10. [Continuous subcutaneous infusion of GnRH agonist: effective dosage in the treatment of endometriosis and its influence on the ovarian response to human menopausal gonadotropin].
Masaoka K; Kitazawa M; Watanabe H; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):729-36. PubMed ID: 2504848
[TBL] [Abstract][Full Text] [Related]
11. [Androgens and other hormones in buserelin therapy].
Fuchs U; Zwirner M
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
[TBL] [Abstract][Full Text] [Related]
12. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
13. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
Raitz von Frentz M; Schweppe KW
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
[TBL] [Abstract][Full Text] [Related]
15. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis.
Ohtsuka S; Terakawa N; Shimizu I; Sakata M; Mizutani T; Miyake A; Tanizawa O; Aono T
Endocrinol Jpn; 1989 Aug; 36(4):611-9. PubMed ID: 2510993
[TBL] [Abstract][Full Text] [Related]
16. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
[TBL] [Abstract][Full Text] [Related]
17. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
Shaw RW; Matta W
Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
[TBL] [Abstract][Full Text] [Related]
18. Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH.
Okuda K; Ushiroyama T; Yoshikawa M; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1889-93. PubMed ID: 3145318
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
Schindler AE; Bühler K; Mettler L; Fuchs U; Cirkel U; Ochs H; Schweppe KW; Koch R
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
[TBL] [Abstract][Full Text] [Related]
20. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
